CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice

Rationale

Whilst cannabinoid CB₂ receptors were thought to exist predominantly in immune cells in the periphery, the recent discovery of CB₂ receptors in the brain has led to an increased interest in the role of these central CB₂ receptors. Several studies have reported an association with CB₂ receptors and schizophrenia. Sensorimotor gating deficits occur in schizophrenia patients and can be induced in animals using psychotomimetic drugs such as N-methyl-D-aspartate (NMDA) receptor antagonists.

Objectives

The aim of this study was to investigate the effect of CB₂ ligands on sensorimotor gating, either alone, or on sensorimotor gating deficits induced by the NMDA receptor antagonist MK-801 in mice.

Method

The effects of CB₂ receptor ligands on prepulse inhibition (PPI), an operational measure of sensorimotor gating, alone or when administrated in combination with MK-801, in Balb-C mice were evaluated.

Results

The CB₂ receptor agonist JWH015 had no significant effect on PPI alone but reversed disruptions in PPI induced by MK-801. This effect was blocked by co-administration of the CB₂ receptor antagonist AM630, but not by co-administration of the CB₁ receptor antagonist AM251, indicating a CB₂-mediated effect. The mixed CB₁/CB₂ receptor agonist JWH203 was partially able to reverse MK-801-induced PPI disruptions. Neither the CB₂ receptor antagonist AM630 nor the CB₁ receptor antagonist AM251 had any significant effect alone or on MK-801-induced disruptions in PPI.

Conclusions

CB₂ receptor agonism reversed MK-801 disruptions in sensorimotor gating deficits in mice, indicating that CB₂ agonism may have a protective effect against aspects of drug-induced psychosis.